Capecitabine, oxaliplatin, radiotherapy, and excision (CORE) in patients with MRI-defined locally advanced rectal adenocarcinoma: Results of an international multicenter phase II study

H.J.T. Rutten(Radboud University Nijmegen), Philip Quirke(University of Leeds), Marc Peeters(University of Antwerp), David Sebag‐Montefiore(University of Leeds), Rob Glynne‐Jones(Mount Vernon Cancer Centre), Gina Brown(Imperial College Healthcare NHS Trust), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Éric Rullier(Bordeaux Population Health), Cornelis JH van de Velde(Leiden University), Stefano Ricci(Radboud University Nijmegen)
Journal of Clinical Oncology
June 20, 2006
10.1200/jco.2006.24.18_suppl.3528
Cited by 74

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k